1 Min Read
April 2 (Reuters) - Synlogic Inc:
* SYNLOGIC DOSES FIRST PATIENT IN PHASE 1B/2A TRIAL OF SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH CIRRHOSIS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.